108 related articles for article (PubMed ID: 35203458)
1. Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects.
Gion M; Pérez-García JM; Llombart-Cussac A; Sampayo-Cordero M; Cortés J; Malfettone A
Ther Adv Med Oncol; 2021; 13():17588359211059587. PubMed ID: 34868353
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of
Tang X; Wu J; Chen Y; Wang D; Wang T; Weng Y; Zhu Z; Peng R; Wang Y; Yan F
Cancer Biother Radiopharm; 2024 Mar; ():. PubMed ID: 38527246
[No Abstract] [Full Text] [Related]
3. Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.
Güler EN
Eur J Breast Health; 2017 Oct; 13(4):168-174. PubMed ID: 29082373
[TBL] [Abstract][Full Text] [Related]
4. Which Patients Need Chemotherapy? From Pathological Risk Factors to Gene Signatures and Evaluation of Endocrine Response.
Schmidt M
Breast Care (Basel); 2023 Dec; 18(6):422-427. PubMed ID: 38125921
[TBL] [Abstract][Full Text] [Related]
5. Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.
Varnier R; Sajous C; de Talhouet S; Smentek C; Péron J; You B; Reverdy T; Freyer G
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638325
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer.
Morganti S; Parsons HA; Lin NU; Grinshpun A
NPJ Breast Cancer; 2023 May; 9(1):43. PubMed ID: 37225714
[TBL] [Abstract][Full Text] [Related]
7. Exploring Prognostic Gene Factors in Breast Cancer via Machine Learning.
Ma Q; Chen L; Feng K; Guo W; Huang T; Cai YD
Biochem Genet; 2024 Feb; ():. PubMed ID: 38383836
[TBL] [Abstract][Full Text] [Related]
8. Interplay between LncRNAs and microRNAs in Breast Cancer.
Schwarzenbach H; Gahan PB
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175800
[TBL] [Abstract][Full Text] [Related]
9. PET/CT in Patients with Breast Cancer Treated with Immunotherapy.
Vaz SC; Graff SL; Ferreira AR; Debiasi M; de Geus-Oei LF
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174086
[TBL] [Abstract][Full Text] [Related]
10. Effective Combination Therapies for the Treatment of HER2 Cancer.
Kargbo RB
ACS Med Chem Lett; 2023 Mar; 14(3):231-232. PubMed ID: 36923923
[TBL] [Abstract][Full Text] [Related]
11. Machine Learning Methods for Cancer Classification Using Gene Expression Data: A Review.
Alharbi F; Vakanski A
Bioengineering (Basel); 2023 Jan; 10(2):. PubMed ID: 36829667
[TBL] [Abstract][Full Text] [Related]
12. PROCURE European consensus on breast cancer multigene signatures in early breast cancer management.
Curigliano G; Cardoso F; Gnant M; Harbeck N; King J; Laenkholm AV; Penault-Llorca F; Prat A
NPJ Breast Cancer; 2023 Feb; 9(1):8. PubMed ID: 36828834
[TBL] [Abstract][Full Text] [Related]
13. Addressing the Clinical Feasibility of Adopting Circulating miRNA for Breast Cancer Detection, Monitoring and Management with Artificial Intelligence and Machine Learning Platforms.
Ling L; Aldoghachi AF; Chong ZX; Ho WY; Yeap SK; Chin RJ; Soo EZX; Khor JF; Yong YL; Ling JL; Yan NS; Ong AHK
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499713
[TBL] [Abstract][Full Text] [Related]
14. Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.
Luo X; Zhang Q; Chen H; Hou K; Zeng N; Wu Y
Front Oncol; 2022; 12():907684. PubMed ID: 35720010
[TBL] [Abstract][Full Text] [Related]
15. Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.
Solek J; Chrzanowski J; Cieslak A; Zielinska A; Piasecka D; Braun M; Sadej R; Romanska HM
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625798
[TBL] [Abstract][Full Text] [Related]
16. Gene Expression Profiling in Early Breast Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment Features.
Munkácsy G; Santarpia L; Győrffy B
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203458
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
18. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
19. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
